$AMGN Headlines

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 10:37 AM

$AMGN Headlines

Amgen's stock drops after trial misses secondary endpoint
9:20 a.m. Nov. 4, 2014
- Tomi Kilgore

Amgen's stock drops 2% in premarket trade
9:07 a.m. Nov. 4, 2014
- Tomi Kilgore

Amgen study on cancer treatment misses secondary endpoint
9:06 a.m. Nov. 4, 2014
- Tomi Kilgore

Facebook, Gilead shares fall after hours
6:14 p.m. Oct. 28, 2014
- Sue Chang

Amgen, under investor pressure, outlines strategy
10:05 a.m. Oct. 28, 2014
- MarketWatch.com

Amgen's stock rises after company outlines capital allocation plans
9:07 a.m. Oct. 28, 2014
- Tomi Kilgore

Amgen's stock climbs 3.2% in premarket trade after capital allocation plans
8:55 a.m. Oct. 28, 2014
- Tomi Kilgore

Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln
8:54 a.m. Oct. 28, 2014
- Tomi Kilgore

Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08
8:53 a.m. Oct. 28, 2014
- Tomi Kilgore

Amgen plans to payout 60% of adj. earnings to shareholders through 2018
8:52 a.m. Oct. 28, 2014
- Tomi Kilgore

Amgen plans to raise dividend 30% starting in Q1 2015
8:52 a.m. Oct. 28, 2014
- Tomi Kilgore

Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015
8:51 a.m. Oct. 28, 2014
- Tomi Kilgore

‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks
8:35 a.m. Oct. 28, 2014
- Shawn Langlois

4 more ‘Amazon’ stocks you may want to avoid
8:43 p.m. Oct. 27, 2014
- Philip van Doorn

Newscast: Stocks mixed -- barely
6:46 p.m. Oct. 27, 2014
- MarketWatch

Twitter shares drop in wake of quarterly results
5:07 p.m. Oct. 27, 2014
- Sue Chang

Amgen posts strong results on higher sales
4:57 p.m. Oct. 27, 2014
- MarketWatch.com

Updates, advisories and surprises
4:31 p.m. Oct. 27, 2014
- MarketWatch

Amgen net drops, but adjusted earnings beat views
4:14 p.m. Oct. 27, 2014
- Russ Britt

Amgen GAAP net of $1.61 is below $1.81 view
4:06 p.m. Oct. 27, 2014
- Russ Britt

Global drug tab will breach trillion dollar mark this year

7:41 a.m. Today7:41 a.m. Nov. 20, 2014
- Seeking Alpha

Stocks Boosted by Merck’s Vytorin Data

7:25 a.m. Today7:25 a.m. Nov. 20, 2014
- Barrons.com

Positive clinical trial results for alirocumab presented at AHA meeting

12:35 p.m. Nov. 19, 2014
- Seeking Alpha

Hottest Healthcare Stocks Now – ACOR CBPO CELG AMGN

12:00 p.m. Nov. 19, 2014
- InvestorPlace.com

Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog

11:23 a.m. Nov. 19, 2014
- Zacks.com

#PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates Chaos In New York
6:50 a.m. Nov. 19, 2014
- benzinga.com

#PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates Chaos In New York

6:50 a.m. Nov. 19, 2014
- benzinga.com

Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews

1:00 a.m. Nov. 19, 2014
- Zacks.com

Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

1:00 a.m. Nov. 19, 2014
- Zacks.com

Gilead's Value Without Its Hep C Franchise

4:07 p.m. Nov. 18, 2014
- Seeking Alpha

Zetia Shows Modest Benefit in Reducing Heart Attacks

5:26 p.m. Nov. 17, 2014
- The Wall Street Journal Interactive Edition

Merck Drug Works: Vytorin Study Proves Successful

12:35 p.m. Nov. 17, 2014
- Investors Business Daily

3 Stocks Moving The Drugs Industry Upward

12:03 p.m. Nov. 17, 2014
- TheStreet.com

Jana Partners 13F Filing Shows Moves In Alibaba & Other Big Names

10:34 a.m. Nov. 14, 2014
- benzinga.com

Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences

9:23 a.m. Nov. 14, 2014
- Seeking Alpha

AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial - Analyst Blog

5:10 p.m. Nov. 13, 2014
- Zacks.com

Amgen Shares Consolidating Ahead Of More Gains?

12:25 p.m. Nov. 13, 2014
- benzinga.com

3 Stocks Underperforming Today In The Drugs Industry

12:06 p.m. Nov. 13, 2014
- TheStreet.com

ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination

9:52 a.m. Nov. 13, 2014
- Seeking Alpha

10 Must-Own Stocks With Great Earnings, Sales and Guidance

12:15 a.m. Nov. 13, 2014
- InvestorPlace.com

Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel
8:01 a.m. Nov. 19, 2014
- BusinessWire - BZX

Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels
4:00 p.m. Nov. 18, 2014
- PR Newswire - PRF

Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
4:05 p.m. Nov. 17, 2014
- GlobeNewswire

Amgen To Present At The Jefferies Global Healthcare Conference
4:15 p.m. Nov. 14, 2014
- PR Newswire - PRF

Critical Alerts For Caesars Entertainment, Orexigen Therapeutics, Amazon.com, Toyota Motor and Amgen Released By InvestorsObserver
9:31 a.m. Nov. 13, 2014
- PR Newswire - PRF

Biothera Names Carey Anderson VP of Regulatory Affairs
9:30 a.m. Nov. 13, 2014
- BusinessWire - BZX

Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions
4:35 p.m. Nov. 12, 2014
- PR Newswire - PRF

Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab
4:01 p.m. Nov. 12, 2014
- PR Newswire - PRF

The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide
9:00 a.m. Nov. 12, 2014
- PR Newswire - PRF

Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
4:01 p.m. Nov. 11, 2014
- PR Newswire - PRF

Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth
2:24 p.m. Nov. 10, 2014
- PR Newswire - PRF

VYCOR: "On the Cusp of the Next Big Healthcare Trend"
9:23 a.m. Nov. 10, 2014
- ACCESSWIRE

FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
9:15 a.m. Nov. 10, 2014
- PR Newswire - PRF

Ziarco Raises $33.1 Million in Series B Financing
7:01 a.m. Nov. 10, 2014
- GlobeNewswire

Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
8:50 a.m. Nov. 7, 2014
- PR Newswire - PRF

Amgen To Present At The Credit Suisse Annual Healthcare Conference
4:30 p.m. Nov. 6, 2014
- PR Newswire - PRF

Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014
4:01 p.m. Nov. 6, 2014
- PR Newswire - PRF

Cloud Pharmaceuticals Announces World-Class Board of Directors
8:00 a.m. Nov. 5, 2014
- PR Newswire - PRF

Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer
9:00 a.m. Nov. 4, 2014
- PR Newswire - PRF

Karyopharm Appoints J. Scott Garland to Its Board of Directors
7:00 a.m. Nov. 4, 2014
- GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Concierge Pediatric Care at Weill Cornell Launches

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Amwell Revolutionizes Digital Care Platforms in 2026

Amwell's Bold Move in Virtual Care Funny how in today’s digital age, where everyone is glued to their screens, healthcare can still feel like trying to piece together a jigsaw puzzle with missing pieces. But Amwell seems to have cracked the code, redefining digital care delivery like few others. Just recently, they bagged Frost & Sullivan's 2026 United States Technology...

Papa John's Faces Securities Class Action Over Missteps

Papa John's Stock Takes a Nosedive Here's a hot potato for you—Papa John's International, Inc. (NASDAQ: PZZA) just got slapped with a securities class action. This ain't a pie you want a slice of, not after the dough they lost in a day's trading frenzy. On August 6, our friends at Papa John's sent their investors scrambling as their stock tumbled from $29.75 to a stark...

2026 AI Talent Study Reveals Growth and Gaps

Pushing Forward Yet Stumbling on the Details We've got a fresh scoop from the AI Leaders Council: They just rolled out their 2026 Corporate AI Talent Study. What's the big fuss? Well, they're tracking how companies are cozying up to artificial intelligence. Let's just say it's a mixed bag this time around. While almost everyone jumped on the AI bandwagon, only a scant 3%...

GlocalMe Unveils Mobile Connectivity Innovations at IFA 2026

Stepping into the Connectivity Future at IFA 2026 GlocalMe, a name synonymous with global mobile connections, made a splash at the IFA 2026 in Berlin. Equipped with a lineup built for the future, their presentation focused on lifestyle gadgets designed for constant online access. In a world where digital connection feels as vital as air, they've aligned perfectly with the...

EF English Live's Approach to Workplace Confidence

Pioneering English Confidence for the Global Workplace Stepping into a meeting with international partners requires more than just textbook knowledge of English. It's about confidently expressing ideas, adapting on the fly, and engaging with global colleagues. Enter EF English Live, a leader in transforming workplace communication through targeted English learning. Expert...

Potomac Edison Eyes Rate Hike for System Overhaul

FirstEnergy's Potomac Edison Pushes for Rate Adjustment The walls are closing in on the energy sector, and Potomac Edison is seizing the moment. With their proposed $52.8 million rate adjustment, they're not only aiming to keep the lights on but to power up their entire infrastructure game. It's a gutsy move, particularly in volatile times. The Price Tag: Weighing Costs...

NOVOSENSE's Bold Performance Amid Rapid IC Demand

Surge in Revenue Growth Marks a Milestone for NOVOSENSE Give a pat on the back to NOVOSENSE (HKEX: 02676), because reporting a robust 66.73% bump in first-half revenue isn't small potatoes in today's tech landscape. This translates to around $374.54 million rolling into their coffers, which is quite a spectacle if you're watching the trend of sequential revenue growth...

Orbis Celebrates 20 Years of Eye Care in Macau

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

Rho Adds Credit Card Payments to Invoices

Rho's New Game: Credit Card Payments on Invoices Ah, the wonderful world where your invoices can finally ride the plastic wave! Rho, that scrappy finance platform everyone's been chattering about, just rolled out a card payment feature. Yep, from credit cards to Google Pay, they’re letting businesses skip the usual financial hurdles and get their dough directly from...